The cumulative biomarker data from these trials followed a similar theme: patients with moderate to severe eosinophilic asthma and elevated baseline blood eosinophils received anti-IL5 therapy; blood eosinophils quickly dropped, then exacerbation rates decreased, asthma control improved, total steroid dose decreased, and quality-of-life metrics improved. Here, IL5 is linked to asthma.